Coagulation Factor Deficiency Market Report 2026

The coagulation factor deficiency market size has grown strongly in recent years. It will grow from $4.93 billion in 2025 to $5.3 billion in 2026 at a compound annual growth rate (CAGR) of 7.6%. The growth in the historic period can be attributed to improved diagnosis of bleeding disorders, wider availability of plasma-derived therapies, expansion of hemophilia treatment centers, increased patient awareness programs, growth in specialty healthcare services.

The coagulation factor deficiency market size is expected to see strong growth in the next few years. It will grow to $7.05 billion in 2030 at a compound annual growth rate (CAGR) of 7.4%. The growth in the forecast period can be attributed to advancements in gene therapy development, rising demand for personalized bleeding disorder treatments, expansion of home care treatment models, increasing focus on reducing treatment frequency, growing investments in rare disease therapeutics. Major trends in the forecast period include increasing adoption of recombinant coagulation factors, rising use of gene therapy-based treatments, growing preference for prophylactic treatment regimens, expansion of home-based infusion therapies, enhanced focus on long-acting factor products.

The growing incidence of blood-related disorders is expected to drive the expansion of the coagulation factor deficiency market in the coming years. Blood-related disorders encompass a range of conditions that affect the production, function, or composition of blood cells, platelets, or plasma, resulting in problems such as anemia, impaired clotting, or immune system deficiencies. The rise in these disorders is attributed to factors including aging populations, genetic predisposition, increased awareness, environmental influences, lifestyle changes, the rising burden of chronic diseases, and advances in diagnostic technologies that support earlier identification. Coagulation factor deficiency therapies play a crucial role in managing blood-related disorders by supplying essential clotting factors needed to prevent or control excessive bleeding in conditions such as hemophilia, where the body’s natural clotting ability is compromised. For example, in September 2024, according to the Leukemia and Lymphoma Society, a US-based professional organization, one person in the US is diagnosed with leukemia, lymphoma, or myeloma every three minutes. In 2024, an estimated 187,740 individuals were expected to face these cancers, accounting for 9.4% of the projected 2,001,140 new cancer cases in the US. Additionally, in May 2024, according to the National Health Service England, a UK-based government-funded healthcare system, around 17,000 people in England were living with sickle cell disease, an inherited blood disorder, with approximately 250 new cases diagnosed each year. Therefore, the increasing incidence of blood-related disorders is contributing to the growth of the coagulation factor deficiency market.

Major companies operating in the coagulation factor deficiency market are increasingly concentrating on the development of advanced therapies, such as one-time gene therapy, to deliver long-term or potentially curative treatment options for patients with bleeding disorders like hemophilia, thereby reducing dependence on lifelong clotting factor infusions. One-time gene therapy involves introducing or modifying genetic material within a patient’s cells to treat or cure a disease, with the objective of achieving sustained or permanent therapeutic benefits following a single administration. For instance, in April 2024, Pfizer Inc., a US-based pharmaceutical and biotechnology company, announced that the US Food and Drug Administration approved BEQVEZ (fidanacogene elaparvovec-dzkt) for the treatment of adults with moderate to severe hemophilia B who are currently receiving factor IX prophylaxis therapy. This therapy is a one-time adeno-associated virus-based gene treatment designed to deliver a functional copy of the factor IX gene encoding a high-activity variant into transduced cells. As a result, patients with hemophilia B are able to produce factor IX themselves following a single treatment, rather than requiring frequent factor IX infusions.

In March 2024, ReciBioPharm, a US-based contract development and manufacturing organization in the pharmaceutical industry, partnered with GeneVentiv Therapeutics to advance the development of a universal adeno-associated virus-based gene therapy for hemophilia, aimed at treating patients with inhibitors for the first time. Through this collaboration, ReciBioPharm will support and accelerate the development of the therapy using its advanced AAV manufacturing platform. GeneVentiv Therapeutics is a US-based preclinical gene therapy company.

Major companies operating in the coagulation factor deficiency market are Pfizer Inc., Bayer HealthCare Pharmaceuticals, Sanofi Genzyme, Novo Nordisk A/S, Baxter International Inc., CSL Behring LLC, Grifols S.A., Octapharma AG, Takeda Pharmaceutical Company Limited, Swedish Orphan Biovitrum AB, Kedrion Biopharma Inc., Shanghai RAAS Blood Products Co. Ltd., LFB S.A., Biotest AG, BioMarin Pharmaceutical Inc., uniQure, Prothya Biosolutions, Bio Products Laboratory Ltd, Green Cross Corporation, Freeline Therapeutics, Aptevo Therapeutics, Hema Biologics LLC, Generation Bio Co, Intellia Therapeutics Inc.

North America was the largest region in the coagulation factor deficiency market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the coagulation factor deficiency market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the coagulation factor deficiency market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are impacting the coagulation factor deficiency market by increasing costs of imported biologics manufacturing equipment, plasma fractionation materials, specialized reagents, and cold-chain logistics components. North America and Europe are most affected due to reliance on cross-border sourcing of plasma-derived inputs and biologics infrastructure, while Asia-Pacific faces higher costs for advanced therapy imports. These tariffs are raising production and treatment costs and influencing pricing strategies for factor concentrates. However, they are also encouraging domestic plasma collection expansion, local biologics manufacturing investments, and regional supply chain strengthening for critical therapies.

The coagulation factor deficiency market research report is one of a series of new reports that provides coagulation factor deficiency market statistics, including coagulation factor deficiency industry global market size, regional shares, competitors with a coagulation factor deficiency market share, detailed coagulation factor deficiency market segments, market trends and opportunities, and any further data you may need to thrive in the coagulation factor deficiency industry. This coagulation factor deficiency market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Coagulation factor deficiency is a condition in which the body lacks one or more clotting factors required for normal blood coagulation, resulting in prolonged bleeding or difficulty in controlling bleeding. These deficiencies are managed using clotting factor concentrates and other therapies that help prevent and control bleeding episodes in patients with disorders such as hemophilia.

The primary product types for coagulation factor deficiency include recombinant coagulation factor concentrates, plasma-derived coagulation factor concentrates, biologics, desmopressin, and others. Recombinant coagulation factor concentrates are laboratory-produced proteins developed to replace missing or deficient clotting factors in patients. The major deficiency types include hemophilia A, hemophilia B, von Willebrand disease, factor XI deficiency, factor XIII deficiency, and others. These treatments are utilized across various end users, including hospitals, clinics, home care settings, and others.

The coagulation factor deficiency market consists of sales of factor VIII concentrates, prothrombin complex concentrates, and fresh frozen plasma (FFP). Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.